Table 1 General and clinical data of migraineurs and control subjects (median ± interquartile range)
| Â | Episodic migraine patients | Healthy control subjects |
|---|---|---|
Gender | Female | Female |
Age (years) | 33.22 ± 9.07 | 30.50 ± 12.77 |
Number of patients/samples in different subgroups according to the different comparisons | All patients, n = 50 Interictal sample, n = 38 Ictal sample, n = 12 | n = 34 No regular headache syndromes, chronic diseases and drugs. |
All interictal patients, n = 47 Migraine with aura samples, n = 11 Migraine without aura samples, n = 36 | ||
All Migraine without aura patients n = 38 Interictal samples, n = 28 Ictal samples, n = 10 | ||
Clinical data of Migraine without aura patients (ninterictal samples = 36, nictal samples = 10) | ||
Disease Duration (years) | 12.50 ± 15.00 | |
Attack frequency (attack/year) | 29.50 ± 29.50 | |
Visual analogue scale (VAS) | moderate n = 7, severe n = 29 | |
Allodynia | No n = 22, Yes n = 14 | |
Menstruation | No n = 20, Yes n = 16 | |
Contraceptives | No n = 25, Yes n = 11 | |
Prophylactic therapy before the interictal sampling | No n = 27, Yes n = 9 (iprazochrome + magnesium orotate n = 4, topiramate n = 4, valproic acid n = 1) | |
Regular attack therapy | eletriptan, sumatriptan > diclophenac > acetylsalicylic acid + metoclopramide, indometacin, nimesulid, naproxen | |
Last attack before the interictal cupping (days) | 7.00 ± 9.00 | |
Prophylactic therapy before ictal cupping | No n = 7, Yes n = 3 (iprazochrome + magnesium orotate n = 1, topiramate n = 2 | |
Ictal sampling (ICHD3rd symptoms) | Beginning of attack (hours) Severity of pain (VAS) Previous last attack (days) | 7.50 ± 18.75 |
8.00 ± 1.00 | ||
16.50 ± 14.00 | ||